Reading Time: 2 minutesIntroduction Osteoporosis, a condition characterized by weakened bones and an increased risk of fractures, poses a significant health challenge to American males. Traditional treatments have focused on bisphosphonates and other medications, but recent research has shifted towards exploring the potential of growth hormone therapies. Serostim, a recombinant human growth hormone, has been at the forefront of these investigations. This article delves into a groundbreaking study involving over 1,000 participants across the United States, examining the long-term effects of Serostim on bone density in American males with osteoporosis. Study Design and Methodology The study was a multicenter, randomized, double-blind, placebo-controlled trial … Continue reading →